Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia
- PMID: 25827696
- PMCID: PMC6074560
- DOI: 10.5144/0256-4947.2014.396
Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia
Abstract
Background and objectives: Middle Eastern respiratory syndrome caused by novel coronavirus (MERS CoV) has been a major public health challenge since it was first described in 2012 in Saudi Arabia. So far, there is no effective treatment for this serious illness, which features a high mortality rate. We report an initial experience of the use of ribavirin and interferon (IFN)-a2b in the management of MERS CoV at a tertiary care hospital.
Design and settings: A case series of 6 patients admitted with a confirmed diagnosis of MERS CoV were treated with ribavirin and IFN-a2b in addition to supportive management. The patients' demographics, clinical parameters, and outcomes were recorded. Fifty-four close contacts of these patients were screened for MERS CoV.
Methods: Six patients with MERS CoV infection were included in this study. Four cases featured symptomatic disease, including pneumonia and respiratory failure, while 2 were asymptomatic close contacts of the MERS CoV patients. The MERS CoV infection was confirmed by reverse transcription-polymerase chain reaction detection of the consensus viral RNA targets upstream of the E gene (UPE) and open reading frame (ORF1b) on a sputum sample. The patients' demographics, comorbid conditions, time to diagnosis and initiation of treatment, and clinical outcomes were recorded.
Results: Three out of 6 patients who had comorbid conditions died during the study period, while 3 had suc.cessful outcomes. The diagnosis and treatment was delayed by an average of 15 days in those patients who died. Only 2 close contacts out of the 54 screened (3.7%) were positive for MERS CoV.
Conclusion: Treatment with ribavirin and IFN-a2b may be effective in patients infected with MERS CoV. There appears to be a low infectivity rate among close contacts of MERS CoV patients.
Figures
Similar articles
-
Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection.BMC Infect Dis. 2019 Oct 22;19(1):870. doi: 10.1186/s12879-019-4555-5. BMC Infect Dis. 2019. PMID: 31640578 Free PMC article.
-
MERS-CoV: Understanding the Latest Human Coronavirus Threat.Viruses. 2018 Feb 24;10(2):93. doi: 10.3390/v10020093. Viruses. 2018. PMID: 29495250 Free PMC article. Review.
-
The calm before the storm: clinical observations of Middle East respiratory syndrome (MERS) patients.J Chemother. 2018 May;30(3):179-182. doi: 10.1080/1120009X.2018.1429236. Epub 2018 Feb 1. J Chemother. 2018. PMID: 29385908
-
Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases.Antivir Ther. 2015;20(1):87-91. doi: 10.3851/IMP2792. Epub 2014 May 15. Antivir Ther. 2015. PMID: 24831606
-
Severe acute respiratory syndrome vs. the Middle East respiratory syndrome.Curr Opin Pulm Med. 2014 May;20(3):233-41. doi: 10.1097/MCP.0000000000000046. Curr Opin Pulm Med. 2014. PMID: 24626235 Review.
Cited by
-
[Use of ribavirin in viruses other than hepatitis C. A review of the evidence].Enferm Infecc Microbiol Clin. 2019 Nov;37(9):602-608. doi: 10.1016/j.eimc.2018.05.008. Epub 2018 Jun 12. Enferm Infecc Microbiol Clin. 2019. PMID: 38620198 Free PMC article. Review. Spanish.
-
Controversies' clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages.World J Clin Cases. 2021 Jul 6;9(19):5135-5178. doi: 10.12998/wjcc.v9.i19.5135. World J Clin Cases. 2021. PMID: 34307564 Free PMC article.
-
Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.Eur J Pharmacol. 2021 Sep 5;906:174248. doi: 10.1016/j.ejphar.2021.174248. Epub 2021 Jun 12. Eur J Pharmacol. 2021. PMID: 34126092 Free PMC article.
-
Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections.Front Immunol. 2021 May 19;12:660298. doi: 10.3389/fimmu.2021.660298. eCollection 2021. Front Immunol. 2021. PMID: 34093548 Free PMC article. Review.
-
Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review.Ren Fail. 2020 Nov 9;43(1):1-15. doi: 10.1080/0886022X.2020.1847724. Ren Fail. 2020. PMID: 33256491 Free PMC article.
References
-
- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820. - PubMed
-
- Ministry of Health [webpage on the Internet] Statistics and daily reports. Kingdom of Saudi Arabia: Ministry of Health; 2014. [Accessed July 15, 2014]. Available from: http://www.moh.gov.sa/en/ccc/PressReleases/Pages/default.aspx.
-
- Ministry of Health. Case Definition and Surveillance Guidance for MERS-CoV Testing in Saudi Arabia. Saudi Arabia: Ministry of Health; 2014. [Accessed May 13, 2014]. Available from. http://www.moh.gov.sa/en/Documents/MoHCaseDefinitionMERSCoVVersion-May13....
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources